R. Corradetti et al., ANTAGONIST PROPERTIES OF (-)-PINDOLOL AND WAY-100635 AT SOMATODENDRITIC AND POSTSYNAPTIC 5-HT1A RECEPTORS IN THE RAT-BRAIN, British Journal of Pharmacology, 123(3), 1998, pp. 449-462
1 The aim of the present work was to characterize the 5-hydroxytryptam
ine(1A) (5-HT1A) antagonistic actions of (-)-pindolol and WAY 100635 e
thoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl) cyclohexane carboxam
ide). Studies were performed on 5-HT1A receptors located on 5-hydroxyt
ryptaminergic neurones in the dorsal raphe nucleus (DRN) and on pyrami
dal cells in the CA1 and CA3 regions of the hippocampus in rat brain s
lices. 2 Intracellular electrophysiological recording of CA1 pyramidal
cells and 5-hydroxytryptaminergic DRN neurones showed that the 5-HT1A
receptor agonist 5-carboxamidotryptamine (5-CT) evoked in both cell t
ypes a concentration-dependent cell membrane hyperpolarization and a d
ecrease in cell input resistance. On its own, (-)-pindolol did not mod
ify the cell membrane potential and resistance at concentrations up to
10 mu M, but it antagonized the 5-CT effects in a concentration-depen
dent manner. Similar antagonism of 5-CT effects was observed in the CA
3 hippocampal region. (-)-Pindolol also prevented the 5-HT1A receptor-
mediated hyperpolarization of CAI pyramidal cells due to 5-HT (15 mu M
). In contrast, the 5-HT-induced depolarization mediated by presumed 5
-HT4 receptors persisted in the presence of 3 mu M (-)-pindoloi. 3 In
the hippocampus, (-)-pindolol completely prevented the hyperpolarizati
on of CA1 pyramidal cells by 100 nM 5-CT (IC50=92 nM; apparent K-B=20.
1 nM), and of CA3 neurones by 300 nM 5-CT (IC50=522 nM; apparent K-B=1
15.1 nM). The block by (-)-pindolol was surmounted by increasing the c
oncentration of 5-CT, indicating a reversible and competitive antagoni
stic action. 4 Extracellular recording of the firing rate of 5-hydroxy
tryptaminergic neurones in the DRN showed that (-)-pindolol blocked, i
n a concentration-dependent manner, the decrease in firing elicited by
100 nM 5-CT (IC50=598 nM; apparent K-B=131.7 nM) or 100 nM ipsapirone
(IC50=132.5 nM; apparent K-B=124.9 nM). The effect of (-)-pindolol wa
s surmountable by increasing the concentration of the agonist. Intrace
llular recording experiments showed that 10 mu M (-)-pindolol were req
uired to antagonize completely the hyperpolarizing effect of 100 nM 5-
CT. 5 In vivo labelling of brain 5-HT1A receptors by i.v. administrati
on of [H-3]-WAY 100635 ([O-methyl-H-3]-N-(2-(4-(2-methoxyphenyl)-1 zin
yl)ethyl-N-(2-pyridyl)cyclo-hexane-carboxamide) was used to assess the
ir occupancy following in vivo treatment with (-)-pindolol. (-)-Pindol
ol (15 mg kg(-1)) injected i.p. either subchronically (2 day-treatment
before i.v. injection of [H-3]-WAY 100635) or acutely (20 min before
i.v. injection of [H-3]-WAY 100635) markedly reduced [H-3]-WAY 100635
accumulation in all 5-HT1A receptor-containing brain areas. In particu
lar, no differences were observed in the capacity of (-)-pindolol to p
revent [H-3]-WAY 100635 accumulation in the DRN and the CA1 and CA3 hi
ppocampal areas. 6 Intracellular electrophysiological recording of 5-h
ydroxytryptaminergic DRN neurones showed that WAY 100635 prevented the
hyperpolarizing effect of 100 nM 5-CT in a concentration-dependent ma
nner (IC50=4.9 nM, apparent K-B=0.25 nM). In CA1 pyramidal cells, hype
rpolarization induced by 50 nM 5-CT was also antagonized by WAY 100635
(IC50=0.80 nM, apparent K-B=0.28 nM).